Author

A. Ager

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 4 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Dritsoula· 1 shared A. H. Watson· 1 shared A.-M. Lyne· 1 shared B. Adkins· 1 shared B. Aktas· 1 shared C. Camilli· 1 shared C. E. Bowers· 1 shared C. Lobry· 1 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Dritsoula

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Metabolically Primed Multipotent Hematopoietic Progenitors Fuel Innate Immunity

J. Cosgrove, A.-M. Lyne, I. Rodriguez, V. Cabeli, S. Tenreira-Bento, E. Tubeuf, E. Russo, F. Tabarin, Y. Belloucif, S. Maleki-Toyserkani, S. Reed, F. Monaco, A. Ager, C. Lobry, P. Bousso, , L. Perie

The paper identifies metabolic cues that guide innate immune cell development by showing how HSPC metabolism influences myeloid differentiation and immune cell production.

bioRxiv · Jan 24, 2023 · PreprintImmunology

LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency

M. N. O'Connor, D. M. Kallenberg, R. Jackstadt, A. H. Watson, M. Alatsatianos, J. Ohme, C. Camilli, C. Pilotti, A. Dritsoula, C. E. Bowers, L. Dowsett, J. George, X. Wang, A. Ager, O. J. Sansom, , J. Greenwood

This study shows that LRG1 promotes tumor vascular dysfunction and suppresses immunotherapy effectiveness, with its inhibition enhancing therapeutic outcomes in mouse cancer models.

bioRxiv · Oct 12, 2020Cancer Biology

Quantifying the Limits of Immunotherapies in Mice and Men

L. V. Brown, E. A. Gaffney, A. Ager, J. Wagg, M. C. Coles

The paper quantifies the difference in CART-cell delivery rates between humans and mice, finding human delivery rates are much lower, suggesting higher doses may be needed for efficacy in solid tumours.

bioRxiv · Mar 9, 2020 · PreprintCancer Biology

The eIF2α Kinase Heme Regulated Inhibitor (HRI) Protects The Host From Infection By Regulating Intracellular Pathogen Trafficking

W. Bahnan, J. Boucher, P. Gayle, N. Shrestha, M. Rosen, B. Aktas, B. Adkins, A. Ager, W. Khan, K. Schesser

This study shows that HRI protects against Listeria monocytogenes infection by restricting pathogen trafficking and antigen presentation.

bioRxiv · May 26, 2017Immunology